Clinical trial
Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected…
NCT00051844 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00051844 |
|---|---|
| Title | Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen |
| Official title | A Double Blind- Randomized, Placebo-controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Human Immunodeficiency Virus |
| Intervention type | Drug |
| Interventions | Capravirine |
| Enrollment | 179 |
| Start date | Aug 1, 2002 |
| Completion | Nov 1, 2004 |
| First posted | Jan 20, 2003 |
| Last update posted | May 10, 2011 |
| Countries | France, Germany, Italy, South Africa, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: